Senescence-Chips for Radiation Biodosimetry

放射性/核恐怖事件后急性和迟发性辐射损伤的理想生物标志物是 其在组织损伤表现之前出现并可测量，通常在电离后一至几天 辐射（IR）暴露。然而，目前还没有商业平台可以进行测定， 这些生物标志物对于辐射生物剂量测定具有高稳健性、灵敏度和特异性。根据PA- 18-525，Newomics Inc.建议在第二阶段项目中完成其产品的开发， “衰老芯片”，用于快速准确地检测衰老细胞，特别是IR诱导的衰老细胞， 细胞，用于辐射生物剂量测定和医疗对策。第二阶段项目是建立在有前途的 这是我们第一阶段项目的成果。在第一阶段，我们开发了集成微流控芯片， 展示了它们在超高通量分离和去除衰老细胞中的原理验证应用。 全血中的细胞在第二阶段，我们将完成衰老芯片的开发， 商业化，并开发新的多组学分析，用于分析分子标记面板使用Newomics的 突破性的多喷嘴发射器阵列芯片。一旦开发完成，Newomics的集成平台和解决方案 将能够实现低成本、可重复、高度特异性和灵敏度的人外周血的多重测量， 血液用于辐射生物剂量测定，从而作为放射/核医学的现场部署平台 包括紧急分诊和医疗应对措施。

Ideal biomarkers for acute and delayed radiation injury after a radiological/nuclear terrorist incident are those that arise and are measurable prior to manifestation of tissue injuries, typically one to a few days after ionizing radiation (IR) exposure. However, there are currently no commercial platforms that could perform assays for these biomarkers with high robustness, sensitivity, and specificity for radiation biodosimetry. In response to PA- 18-525, Newomics Inc. proposes in this Phase II project to complete development of its product, termed “Senescence-Chips”, for rapid and accurate detection of senescent cells, particularly, IR-induced senescent cells, for radiation biodosimetry and medical countermeasure. The Phase II project is built upon the promising results generated from our Phase I project. In Phase I, we have developed the integrated microfluidic chips, and demonstrated their proof-of-principle applications for ultrahigh-throughput isolation and removal of senescent cells spiked in whole blood. In Phase II, we will complete development of the senescence-chips for commercialization, and develop new multiomics assays for analyzing molecular marker panels using Newomics' breakthrough multinozzle emitter array chips. Once developed, Newomics' integrated platforms and solutions will enable low-cost, reproducible, highly specific and sensitive multiplex measurements of human peripheral blood for radiation biodosimetry, thus serving as a field-deployable platform for radiological/nuclear medical countermeasures including emergency triage and medical responses.